Business updates and supplemental announcement in relation to 2025 annual report
Filed with HKEX · Stock code 2592 · · 3 pages · English
On 6ix: 6ix.com/news/business-updates-and-supplemental-announcement-in-relation-to-2025-annual-report
拨康视云 Cloudbreak Pharma CLOUDBREAK PHARMA INC. 撥康視雲製藥有限公司* (Incorporated in the Cayman Islands with limited liability) (Stock Code: 2592) BUSINESS UPDATES AND SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO 2025 ANNUAL REPORT Reference is made to the annual report of Cloudbreak Pharma Inc. (the “Company”, together with its subsidiaries, the “Group”) for the year ended 31 December 2025 (the “2025 Annual Re
Cloudbreak Pharma, Inc. on 6ix
Earlier from Cloudbreak Pharma
- Suspension of trading
- Cloudbreak Pharma Announces Results of First-of-Its-Kind Patient Survey on Pinguecula, Confirming Significant Unmet Need and Impact on Quality of Life
- Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
- Cloudbreak Pharma to Present at the Stifel 2026 Virtual Ophthalmology Forum
- Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at Eyecelerator @ ARVO 2026
Later from Cloudbreak Pharma
- Appointment of independent non-executive directors and continued suspension of trading
- List of directors and their roles and functions
- Formation of an independent Special committee; delay in publication and despatch of 2026 interim report; and continued suspension of trading
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Cloudbreak Pharma into a list and get an email when it puts out news.
Follow Cloudbreak Pharma